Guy Peachey

1.3k total citations
26 papers, 755 citations indexed

About

Guy Peachey is a scholar working on Physiology, Pulmonary and Respiratory Medicine and Immunology and Allergy. According to data from OpenAlex, Guy Peachey has authored 26 papers receiving a total of 755 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Physiology, 21 papers in Pulmonary and Respiratory Medicine and 12 papers in Immunology and Allergy. Recurrent topics in Guy Peachey's work include Asthma and respiratory diseases (25 papers), Inhalation and Respiratory Drug Delivery (13 papers) and Allergic Rhinitis and Sensitization (12 papers). Guy Peachey is often cited by papers focused on Asthma and respiratory diseases (25 papers), Inhalation and Respiratory Drug Delivery (13 papers) and Allergic Rhinitis and Sensitization (12 papers). Guy Peachey collaborates with scholars based in United Kingdom, United States and Netherlands. Guy Peachey's co-authors include Robert Maykut, Gert‐Jan Braunstahl, Panayiotis Georgiou, J Bruce, Zenon Siergiejko, Clare Peckitt, Nicola J. Smith, Chien‐Wei Chen, J Chlumský and Steven Pascoe and has published in prestigious journals such as CHEST Journal, Journal of Allergy and Clinical Immunology and Clinical Pharmacokinetics.

In The Last Decade

Guy Peachey

24 papers receiving 738 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Guy Peachey United Kingdom 12 707 610 303 58 47 26 755
Cris Roxas United Kingdom 12 576 0.8× 483 0.8× 156 0.5× 124 2.1× 80 1.7× 38 650
Zenon Siergiejko Poland 9 392 0.6× 363 0.6× 157 0.5× 43 0.7× 22 0.5× 46 503
Jean‐Pierre Llanos United States 14 476 0.7× 336 0.6× 152 0.5× 114 2.0× 22 0.5× 41 565
Mary Buatti Small United States 6 495 0.7× 396 0.6× 70 0.2× 78 1.3× 24 0.5× 7 546
Sarah Diver United Kingdom 9 437 0.6× 322 0.5× 111 0.4× 138 2.4× 12 0.3× 26 587
A B Löfroos Sweden 10 599 0.8× 565 0.9× 41 0.1× 24 0.4× 18 0.4× 10 660
Evangelia Fouka Greece 13 246 0.3× 262 0.4× 42 0.1× 51 0.9× 31 0.7× 39 382
Yen Chung United States 10 231 0.3× 167 0.3× 45 0.1× 37 0.6× 11 0.2× 30 298
Michel Djandji United States 11 246 0.3× 180 0.3× 53 0.2× 66 1.1× 11 0.2× 34 302
Matthias Urban Austria 11 147 0.2× 171 0.3× 26 0.1× 36 0.6× 48 1.0× 28 314

Countries citing papers authored by Guy Peachey

Since Specialization
Citations

This map shows the geographic impact of Guy Peachey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Guy Peachey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Guy Peachey more than expected).

Fields of papers citing papers by Guy Peachey

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Guy Peachey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Guy Peachey. The network helps show where Guy Peachey may publish in the future.

Co-authorship network of co-authors of Guy Peachey

This figure shows the co-authorship network connecting the top 25 collaborators of Guy Peachey. A scholar is included among the top collaborators of Guy Peachey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Guy Peachey. Guy Peachey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Oppenheimer, John, Huib A.M. Kerstjens, Louis‐Philippe Boulet, et al.. (2024). Characterization of Moderate and Severe Asthma Exacerbations in the CAPTAIN Study. The Journal of Allergy and Clinical Immunology In Practice. 12(9). 2372–2380.e5. 1 indexed citations
2.
Oppenheimer, John, Nicola A. Hanania, Rekha Chaudhuri, et al.. (2023). Clinic vs Home Spirometry for Monitoring Lung Function in Patients With Asthma. CHEST Journal. 164(5). 1087–1096. 14 indexed citations
3.
Yang, Shuying, Laurie A. Lee, Neal Sule, Andrew Fowler, & Guy Peachey. (2021). Population Pharmacokinetic Modeling of Fluticasone Furoate, Umeclidinium Bromide, and Vilanterol in Patients with Asthma, Using Data from a Phase IIIA Study (CAPTAIN). Clinical Pharmacokinetics. 60(7). 887–896. 1 indexed citations
4.
Gardiner, F, Emílio Pizzichini, Zelie Bailes, et al.. (2021). A Comparison of Clinic Versus Home Spirometry in the CAPTAIN Study. A1348–A1348. 2 indexed citations
5.
6.
Lee, Laurie A., Zelie Bailes, Neil Barnes, et al.. (2020). Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial. The Lancet Respiratory Medicine. 9(1). 69–84. 150 indexed citations
7.
8.
Oppenheimer, John, Edward Kerwin, Huib A.M. Kerstjens, et al.. (2020). Characterising asthma exacerbations in the CAPTAIN trial. 2276–2276. 2 indexed citations
9.
Barbosa, Manuel Pereira, et al.. (2015). Real-life efficacy and safety of omalizumab in Portuguese patients with persistent uncontrolled asthma. Revista Portuguesa de Pneumologia. 21(3). 151–156. 8 indexed citations
10.
Braunstahl, Gert‐Jan, Janice Canvin, Guy Peachey, Chien‐Wei Chen, & Panayiotis Georgiou. (2014). Healthcare Resource Utilization in Patients Receiving Omalizumab for Allergic Asthma in a Real-World Setting. PubMed. 4(1-2). 57–67. 18 indexed citations
11.
Braunstahl, Gert‐Jan, et al.. (2013). The eXpeRience registry: The ‘real-world’ effectiveness of omalizumab in allergic asthma. Respiratory Medicine. 107(8). 1141–1151. 156 indexed citations
12.
Braunstahl, Gert‐Jan, J Chlumský, Guy Peachey, & Chien‐Wei Chen. (2013). Reduction in oral corticosteroid use in patients receiving omalizumab for allergic asthma in the real-world setting. Allergy Asthma and Clinical Immunology. 9(1). 47–47. 50 indexed citations
13.
Somerville, Laura L., et al.. (2013). Immunogenicity and safety of omalizumab in pre-filled syringes in patients with allergic (IgE-mediated) asthma. Current Medical Research and Opinion. 30(1). 59–66. 15 indexed citations
14.
Braunstahl, Gert‐Jan, J Chlumský, Guy Peachey, Robert Maykut, & Chien‐Wei Chen. (2013). Reduction in oral corticosteroid use in patients with severe allergic (IgE‐mediated) asthma receiving omalizumab in a real‐world setting. Clinical and Translational Allergy. 3(S1). 13 indexed citations
15.
Siergiejko, Zenon, et al.. (2011). Oral corticosteroid sparing with omalizumab in severe allergic (IgE-mediated) asthma patients. Current Medical Research and Opinion. 27(11). 2223–2228. 61 indexed citations
16.
Bousquet, Jean, Zenon Siergiejko, Marc Humbert, et al.. (2011). Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma. Allergy. 66(5). 671–678. 137 indexed citations
17.
Braunstahl, Gert‐Jan, et al.. (2011). Uncontrolled persistent allergic asthma in practice: eXpeRience registry baseline characteristics. Current Medical Research and Opinion. 27(4). 761–767. 16 indexed citations
18.
Braunstahl, Gert‐Jan, et al.. (2011). The eXpeRience registry: Monitoring the “real-world” effectiveness of omalizumab in allergic asthma. 38. 3953. 2 indexed citations
19.
Molimard, Mathiéu, Roland Buhl, Robert Niven, et al.. (2010). Omalizumab reduces oral corticosteroid use in patients with severe allergic asthma: Real-life data. Respiratory Medicine. 104(9). 1381–1385. 65 indexed citations
20.
Beier, Jutta, Kai Michael Beeh, L Brookman, et al.. (2009). Bronchodilator effects of indacaterol and formoterol in patients with COPD. Pulmonary Pharmacology & Therapeutics. 22(6). 492–496. 36 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Cris Roxas Breakdown of academic impact, for papers by Zenon Siergiejko Breakdown of academic impact, for papers by Jean‐Pierre Llanos Breakdown of academic impact, for papers by Mary Buatti Small Breakdown of academic impact, for papers by Sarah Diver Breakdown of academic impact, for papers by A B Löfroos Breakdown of academic impact, for papers by Evangelia Fouka Breakdown of academic impact, for papers by Yen Chung Breakdown of academic impact, for papers by Michel Djandji Breakdown of academic impact, for papers by Matthias Urban
Rankless by CCL
2026